MeiraGTx Holdings PLC
MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also developing AAV-AQP1 in Phase 2 trial for radiation-induced grade 2/3 … Read more
MeiraGTx Holdings PLC (MGTX) - Net Assets
Latest net assets as of September 2025: $-40.56 Million USD
Based on the latest financial reports, MeiraGTx Holdings PLC (MGTX) has net assets worth $-40.56 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($189.47 Million) and total liabilities ($230.03 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-40.56 Million |
| % of Total Assets | -21.41% |
| Annual Growth Rate | N/A |
| 5-Year Change | -71.57% |
| 10-Year Change | N/A |
| Growth Volatility | 61.79 |
MeiraGTx Holdings PLC - Net Assets Trend (2016–2024)
This chart illustrates how MeiraGTx Holdings PLC's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for MeiraGTx Holdings PLC (2016–2024)
The table below shows the annual net assets of MeiraGTx Holdings PLC from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $67.83 Million | -50.91% |
| 2023-12-31 | $138.18 Million | +17.36% |
| 2022-12-31 | $117.74 Million | -36.50% |
| 2021-12-31 | $185.40 Million | -22.28% |
| 2020-12-31 | $238.56 Million | +25.03% |
| 2019-12-31 | $190.80 Million | +135.39% |
| 2018-12-31 | $81.06 Million | +271.14% |
| 2017-12-31 | $-47.37 Million | -176.36% |
| 2016-12-31 | $-17.14 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to MeiraGTx Holdings PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 66764269200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.00K | 0.00% |
| Other Comprehensive Income | $-3.72 Million | -5.48% |
| Other Components | $773.57 Million | 1140.50% |
| Total Equity | $67.83 Million | 100.00% |
MeiraGTx Holdings PLC Competitors by Market Cap
The table below lists competitors of MeiraGTx Holdings PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Xiamen Hexing Packaging Printing Co Ltd
SHE:002228
|
$306.80 Million |
|
Luoyang Jalon Micro-Nano New Materials Co Ltd
SHG:688357
|
$306.92 Million |
|
Kopin Corporation
NASDAQ:KOPN
|
$307.01 Million |
|
Alpargatas S.A
SA:ALPA3
|
$307.02 Million |
|
kneat.com inc.
OTCQX:KSIOF
|
$306.73 Million |
|
Kolon Life Science Inc
KQ:102940
|
$306.72 Million |
|
Solus Advanced Materials Co Ltd
KO:336370
|
$306.72 Million |
|
Saratoga Investment Corp
NYSE:SAR
|
$306.66 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MeiraGTx Holdings PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 138,177,000 to 67,827,000, a change of -70,350,000 (-50.9%).
- Net loss of 147,791,000 reduced equity.
- New share issuances of 59,390,000 increased equity.
- Other comprehensive income decreased equity by 2,284,000.
- Other factors increased equity by 20,335,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-147.79 Million | -217.89% |
| Share Issuances | $59.39 Million | +87.56% |
| Other Comprehensive Income | $-2.28 Million | -3.37% |
| Other Changes | $20.34 Million | +29.98% |
| Total Change | $- | -50.91% |
Book Value vs Market Value Analysis
This analysis compares MeiraGTx Holdings PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.65x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $-0.89 | $7.43 | x |
| 2017-12-31 | $-5.53 | $7.43 | x |
| 2018-12-31 | $4.28 | $7.43 | x |
| 2019-12-31 | $5.75 | $7.43 | x |
| 2020-12-31 | $6.32 | $7.43 | x |
| 2021-12-31 | $4.20 | $7.43 | x |
| 2022-12-31 | $2.61 | $7.43 | x |
| 2023-12-31 | $2.45 | $7.43 | x |
| 2024-12-31 | $0.97 | $7.43 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MeiraGTx Holdings PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -217.89%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -444.10%
- • Asset Turnover: 0.12x
- • Equity Multiplier: 3.98x
- Recent ROE (-217.89%) is below the historical average (-65.22%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-17.77 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-26.31 Million |
| 2018 | -102.23% | 0.00% | 0.00x | 1.20x | $-90.97 Million |
| 2019 | -28.69% | -411.87% | 0.04x | 1.70x | $-73.83 Million |
| 2020 | -24.31% | -372.63% | 0.04x | 1.52x | $-81.85 Million |
| 2021 | -42.91% | -211.03% | 0.12x | 1.73x | $-98.10 Million |
| 2022 | -110.09% | -814.16% | 0.05x | 2.70x | $-141.39 Million |
| 2023 | -60.81% | -599.46% | 0.04x | 2.36x | $-97.84 Million |
| 2024 | -217.89% | -444.10% | 0.12x | 3.98x | $-154.57 Million |
Industry Comparison
This section compares MeiraGTx Holdings PLC's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MeiraGTx Holdings PLC (MGTX) | $-40.56 Million | 0.00% | N/A | $306.80 Million |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |